MYGN

MKT CAP:$449M

Myriad Genetics, Inc.

Market Cap

$449M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$5.08-$1.06 (-17.26%)

Apr 22, 2026

Company Details

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and ...

CEO

Samraat S. Raha

IPO Date

Oct 6, 1995

Website

myriad.com

Key Metrics TTM

Revenue

$825M

+0.2% YoY

Net Income

-$401M

EPS (Diluted)

-$4.33

Free Cash Flow

-$26M

Revenue / Share

$8.86

Gross Margin

70.4%

Operating Margin

-51.0%

Net Margin

-48.5%

FCF Margin

-3.2%

P/S

0.5x

P/E

—

Earnings Reports

Q4 2025

May 5, 2026

PENDING

Q3 2025

Nov 4, 2025

$206M-3.6%EPS -$0.29

Q2 2025

Aug 6, 2025

$213M+0.8%EPS -$3.57

Q1 2025

May 6, 2025

$196M-3.1%EPS -$0.00

FY 2024

Feb 28, 2025

$838M+11.2%EPS -$1.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$161M	$115M	-$43M
Q1 22	$165M	$117M	-$15M
Q2 22	$179M	$130M	-$18M
Q3 22	$156M	$106M	-$45M
Q4 22	$178M	$124M	-$46M
Q1 23	$181M	$122M	-$52M
Q2 23	$184M	$126M	-$114M
Q3 23	$192M	$134M	-$60M
Q4 23	$197M	$135M	-$31M
Q1 24	$202M	$138M	-$28M
Q2 24	$212M	$147M	-$37M
Q3 24	$213M	$150M	-$20M
Q4 24	$211M	$151M	-$39M
Q1 25	$196M	$134M	-$29M
Q2 25	$213M	$152M	-$329M
Q3 25	$206M	$144M	-$23M

Valuation

Quarter	P/S	P/E
Q4 21	3.2x	—
Q1 22	3.0x	—
Q2 22	2.2x	—
Q3 22	2.4x	—
Q4 22	2.0x	—
Q1 23	2.8x	—
Q2 23	2.7x	—
Q3 23	1.8x	—
Q4 23	2.2x	—
Q1 24	2.5x	—
Q2 24	2.7x	—
Q3 24	3.0x	—
Q4 24	1.5x	—
Q1 25	1.0x	—
Q2 25	0.6x	—
Q3 25	0.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$10M	-$13M
Q1 22	-$47M	-$53M
Q2 22	-$50M	-$56M
Q3 22	-$3M	-$21M
Q4 22	-$8M	-$22M
Q1 23	-$33M	-$57M
Q2 23	-$900.0K	-$20M
Q3 23	-$22M	-$40M
Q4 23	-$55M	-$68M
Q1 24	-$19M	-$27M
Q2 24	$3M	-$6M
Q3 24	$700.0K	-$6M
Q4 24	$7M	$700.0K
Q1 25	-$16M	-$25M
Q2 25	-$14M	-$21M
Q3 25	$21M	$18M

Capital Expenditures

Quarter	CapEx
Q4 21	$3M
Q1 22	$6M
Q2 22	$7M
Q3 22	$18M
Q4 22	$15M
Q1 23	$24M
Q2 23	$19M
Q3 23	$18M
Q4 23	$14M
Q1 24	$9M
Q2 24	$9M
Q3 24	$6M
Q4 24	$6M
Q1 25	$8M
Q2 25	$7M
Q3 25	$3M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+10.7%	+10.3%
Q1 22	-4.7%	-18.2%
Q2 22	-5.3%	-6.2%
Q3 22	-6.5%	-18.5%
Q4 22	+10.6%	+9.8%
Q1 23	+9.9%	+29.8%
Q2 23	+2.3%	+50.8%
Q3 23	+22.7%	+25.1%
Q4 23	+10.6%	+1.9%
Q1 24	+11.6%	-1.4%
Q2 24	+15.3%	-16.6%
Q3 24	+11.2%	-7.4%
Q4 24	+7.1%	+9.5%
Q1 25	-3.1%	-2.3%
Q2 25	+0.8%	+118.7%
Q3 25	-3.6%	-1.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$8M	5.2%
Q1 22	$10M	6.1%
Q2 22	$10M	5.8%
Q3 22	$9M	6.0%
Q4 22	$8M	4.6%
Q1 23	$8M	4.1%
Q2 23	$11M	6.1%
Q3 23	$12M	6.0%
Q4 23	$10M	5.3%
Q1 24	$12M	5.9%
Q2 24	$15M	6.9%
Q3 24	$12M	5.8%
Q4 24	$11M	5.2%
Q1 25	$10M	4.8%
Q2 25	$11M	5.0%
Q3 25	$12M	5.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 21	$17M	$142M	—	—
Q1 22	$21M	—	—	$111M
Q2 22	$20M	$127M	—	—
Q3 22	$21M	$131M	—	—
Q4 22	$23M	$147M	—	—
Q1 23	$23M	$152M	—	—
Q2 23	$21M	$218M	—	—
Q3 23	$24M	$136M	—	—
Q4 23	$21M	$33M	—	—
Q1 24	$25M	$71M	$69M	—
Q2 24	$27M	$72M	$73M	—
Q3 24	$29M	$139M	—	—
Q4 24	$32M	—	$284M	—
Q1 25	$28M	$67M	$69M	—
Q2 25	$26M	$67M	$72M	—
Q3 25	$28M	$68M	$71M	—

Revenue Segments

Quarter

Revenue by Geography

Quarter	Non-US	United States
Q4 22	$21M	$157M
Q3 23	$20M	$172M
Q1 24	$19M	$183M
Q2 24	$17M	$195M
Q3 24	$17M	$196M
Q4 24	$15M	$196M
Q1 25	$14M	$182M
Q2 25	$15M	$198M
Q3 25	$14M	$192M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$165M	$103M	$268M
Q2 22	$105M	$100M	$205M
Q3 22	$111M	$83M	$193M
Q4 22	$57M	$58M	$115M
Q1 23	$54M	$25M	$79M
Q2 23	$103M	$19M	$122M
Q3 23	$76M	$10M	$86M
Q4 23	$132M	$9M	$141M
Q1 24	$97M	$7M	$104M
Q2 24	$92M	$5M	$97M
Q3 24	$100M	$0	$100M
Q4 24	$102M	$0	$102M
Q1 25	$92M	$0	$92M
Q2 25	$74M	$0	$74M
Q3 25	$145M	$0	$145M
Q4 25	$150M	$0	$150M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	80M	-2.0%	+7.0%
Q1 22	80M	+0.3%	+5.4%
Q2 22	80M	+0.4%	+4.1%
Q3 22	81M	+0.4%	-1.0%
Q4 22	82M	+1.0%	+2.0%
Q1 23	81M	-0.2%	+1.5%
Q2 23	82M	+0.5%	+1.6%
Q3 23	82M	+0.2%	+1.5%
Q4 23	86M	+5.1%	+5.6%
Q1 24	90M	+4.4%	+10.6%
Q2 24	91M	+0.8%	+10.9%
Q3 24	91M	+0.3%	+11.0%
Q4 24	91M	+0.2%	+5.8%
Q1 25	91M	+0.3%	+1.7%
Q2 25	93M	+1.2%	+2.1%
Q3 25	93M	+0.6%	+2.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$67.0K	2K
Q1 22	$68.7K	2K
Q2 22	$74.7K	2K
Q3 22	$65.2K	2K
Q4 22	$68.4K	3K
Q1 23	$69.7K	3K
Q2 23	$70.6K	3K
Q3 23	$73.8K	3K
Q4 23	$72.8K	3K
Q1 24	$74.9K	3K
Q2 24	$78.3K	3K
Q3 24	$79.0K	3K
Q4 24	$78.0K	3K
Q1 25	$72.6K	3K
Q2 25	$78.9K	3K
Q3 25	$76.2K	3K

Revenue / Employee